Literature DB >> 1542309

Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex.

D McMahon-Pratt1, Y Traub-Cseko, K L Lohman, D D Rogers, S M Beverley.   

Abstract

Immunization with the GP46/M-2 membrane glycoprotein of Leishmania amazonensis has been shown to induce a protective immune response against infection. We have surveyed a variety of trypanosomatid species and genera for the presence and expression of this gene family, information that will be relevant to future vaccine studies against leishmaniasis. Molecular karyotype analysis revealed the presence of GP46/M-2 genes in all members of the Leishmania mexicana complex, Leishmania major, Leishmania donovani, Leishmania tarentolae, and Crithidia fasciculata. In contrast, DNAs from species of the Leishmania braziliensis complex (L. braziliensis, Leishmania guyanensis, and Leishmania panamensis) failed to hybridize to GP46/M-2 probes. Western blot analyses with several polyclonal antisera against the GP46/M-2 protein revealed protein expression in L. major and L. donovani, but not L. panamensis or L. braziliensis. Phylogenetic analysis suggests that a loss of the GP46A gene family occurred following separation of the L. braziliensis complex, prior to speciation events within this complex. These data indicate that GP46/M-2 membrane glycoprotein may not be critical to parasite survival, but may play an ancillary role during the developmental cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542309     DOI: 10.1016/0166-6851(92)90252-f

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  14 in total

Review 1.  Proteoliposomes in nanobiotechnology.

Authors:  P Ciancaglini; A M S Simão; M Bolean; J L Millán; C F Rigos; J S Yoneda; M C Colhone; R G Stabeli
Journal:  Biophys Rev       Date:  2012-01-18

Review 2.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 3.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

4.  Species-specificity in endoplasmic reticulum signal peptide utilization revealed by proteins from Trypanosoma brucei and Leishmania.

Authors:  A Al-Qahtani; M Teilhet; K Mensa-Wilmot
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

5.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

7.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug.

Authors:  Rubén E Varela M; Diana Lorena Muñoz; Sara M Robledo; Bala K Kolli; Sujoy Dutta; Kwang Poo Chang; Carlos Muskus
Journal:  Exp Parasitol       Date:  2009-03-20       Impact factor: 2.011

9.  Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major.

Authors:  Althea A Capul; Suzanne Hickerson; Tamara Barron; Salvatore J Turco; Stephen M Beverley
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.